Vantage logo

Persistence pays off for Kala

The company’s Eysuvis looks set to be approved for dry eye disease, but meeting expectations in this tough market will not be easy.

Vantage logo

Deal hopes revive Reneuron

After years in the wilderness, the UK cell therapy specialist Reneuron could be about to seal a deal with a big US player.